|
|
| (75 intermediate revisions by 16 users not shown) |
| Line 1: |
Line 1: |
| | __NOTOC__ |
| | {{Breast cancer}} |
| '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' | | '''For patient information click [[{{PAGENAME}} (patient information)|here]]''' |
| {{Infobox_Disease |
| |
| Name = Breast cancer |
| |
| Image = Breast DCIS histopathology (1).jpg |
| |
| Caption = Histopathologic image from ductal cell carcinoma in situ (DCIS) of breast. Hematoxylin-eosin stain.|
| |
| DiseasesDB = 1598 |
| |
| ICD10 = {{ICD10|C|50||c|50}} |
| |
| ICD9 = {{ICD9|174}}-{{ICD9|175}} |
| |
| ICDO = |
| |
| OMIM = 114480 |
| |
| MedlinePlus = 000913 |
| |
| MeshID = D001943 |
| |
| }}
| |
| {{Breast cancer}}
| |
| {{CMG}}; '''Assistant Editor(s)-In-Chief:''' [[User:Jack Khouri|Jack Khouri]]
| |
|
| |
| ==[[Breast cancer overview|Overview]]==
| |
|
| |
|
| ==Classification==
| | {{CMG}} {{AE}} {{Soroush}} {{MGS}} {{Ammu}} |
|
| |
|
| [[Image:BCtimeline.jpg|thumb|left|450px|Time line of breast cancer suggesting probable [[heterogeneity]]. Primary breast cancers begin as single (or more) cells which have lost normal regulation of differentiation and proliferation but remain confined within the [[basement membrane]] of the [[duct]] or [[lobule]]. As these cells go through several doublings, at some point they invade through the [[basement membrane]] of the [[duct]] or [[lobule]] and ultimately [[metastasize]] to distant organs.<ref>Breast Cancer: Molecular Genetics, Pathogenesis, and Therapeutics (Contemporary Cancer Research) by Anne M. Bowcock (1999)</ref>]]
| | {{SK}} Breast cancers, Breast carcinoma, Breast carcinomas, Breast neoplasm, Breast tumor, Breast tumors, Breast tumour, Breast malignancy |
| There are numerous ways breast cancer is classified. Like most cancers, breast cancer can be divided into groups based on the tissue of origin, e.g. [[epithelium|epithelial]] ([[carcinoma]]) versus [[stroma]]l ([[sarcoma]]). The vast majority of breast cancers arise from epithelial tissue, i.e. they are carcinomas, which can be divided further into subclassifications (e.g. DCIS versus LCIS versus papillary carcinoma).
| |
|
| |
| Other pathologically based classifications:
| |
| *Location of the tumour origin - breast duct (i.e. ductal) versus breast lobule (i.e. lobular).
| |
| *[[Histology]] - see ''Histologic types'' section.
| |
| *[[Bloom-Richardson grade|Grade of tumour]] - ''well-differentiated'' (looks almost like normal tissue) versus ''poorly differentiated'' (does not look like any normal tissue/mass of proliferating cells) versus ''moderately differentiated'' (somewhere between ''poorly differentiated'' and ''well-differentiated'').
| |
| *[[Cancer staging|Stage]] of the tumour.
| |
| *[[Immunohistochemistry|Immunohistochemical]] marker status - ([[estrogen receptor|ER]] positive versus [[Estrogen receptor|ER]] negative versus [[HER2/neu]] positive versus [[HER2/neu]] negative), e.g. ''[[triple negative breast cancer]]'' which is [[estrogen receptor|ER]] negative, [[progesterone receptor|PR]] negative and [[HER2/neu]] negative.
| |
| *[[TNM classification]] -
| |
| **[[Tumour]] size/invasiveness - presence of invasion (poorer prognosis) versus ''[[in situ]]'' (better prognosis).
| |
| **[[lymph node|Nodal]] status.
| |
| **Presence/absence of [[metastases]].
| |
| ===Pathologic types===
| |
| The latest (2003) [[World Health Organization]] (WHO) classification of tumors of the breast<ref>''Tumours of the breast and female genital organs'', WHO classification of tumours, 2003, ISBN 92 832 2412 4</ref> recommends the following pathological types:
| |
|
| |
|
| '''Invasive breast carcinomas'''
| | ==[[Breast cancer overview|Overview]]== |
| * Invasive ductal carcinoma
| |
| ** Most are "not otherwise specified"
| |
| ** The remainder are given subtypes:
| |
| *** Mixed type carcinoma
| |
| *** Pleomorphic carcinoma
| |
| *** Carcinoma with osteoclastic giant cells
| |
| *** Carcinoma with choriocarcinomatous features
| |
| *** Carcinoma with melanotic features
| |
| * Invasive lobular carcinoma
| |
| * Tubular carcinoma
| |
| * Invasive cribriform carcinoma
| |
| * [[Medullary carcinoma]]
| |
| * Mucinous carcinoma and other tumours with abundant mucin
| |
| ** Mucinous carcinoma
| |
| ** Cystadenocarcinoma and columnar cell mucinous carcinoma
| |
| ** [[Signet ring cell carcinoma]]
| |
| * [[Neuroendocrine]] tumours
| |
| ** Solid neuroendocrine carcinoma ([[carcinoid]] of the breast)
| |
| ** Atypical carcinoid tumour
| |
| ** Small cell / [[oat cell carcinoma]]
| |
| ** Large cell neuroendocrine carcioma
| |
| * Invasive papillary carcinoma
| |
| * Invasive micropapillary carcinoma
| |
| * Apocrine carcinoma
| |
| * Metaplastic carcinomas
| |
| ** Pure epithelial metaplastic carciomas
| |
| *** [[Squamous cell carcinoma]]
| |
| *** Adenocarcinoma with spindle cell metaplasia
| |
| *** Adenosquamous carcinoma
| |
| *** [[Mucoepidermoid carcinoma]]
| |
| ** Mixed epithelial/mesenchymal metaplastic carcinomas
| |
| * Lipid-rich carcinoma
| |
| * Secretory carcinoma
| |
| * Oncocytic carcinoma
| |
| * Adenoid cystic carcinoma
| |
| * Acinic cell carcinoma
| |
| * Glycogen-rich clear cell carcinoma
| |
| * Sebaceous carcinoma
| |
| * Inflammatory carcinoma
| |
| * Bilateral breast carcinoma
| |
| | |
| '''Mesenchymal tumors''' (including [[sarcoma]])
| |
| * Haemangioma
| |
| * Angiomatosis
| |
| * Haemangiopericytoma
| |
| * Pseudoangiomatous stromal hyperplasia
| |
| * Myofibroblastoma
| |
| * Fibromatosis (aggressive)
| |
| * Inflammatory myofibroblastic tumour
| |
| * [[Lipoma]]
| |
| ** Angiolipoma
| |
| * Granular cell tumour
| |
| * [[Neurofibroma]]
| |
| * [[Schwannoma]]
| |
| * Angiosarcoma
| |
| * Liposarcoma
| |
| * Rhabdomyosarcoma
| |
| * Osteosarcoma
| |
| * [[Leiomyoma]]
| |
| * Leiomysarcoma
| |
| | |
| '''Precursor lesions'''
| |
| * Lobular neoplasia
| |
| ** lobular carcinoma in situ
| |
| * Intraductal proliferative lesions
| |
| ** Usual ductal [[hyperplasia]]
| |
| ** Flat epithelial hyperplasia
| |
| ** Atypical ductal hyperplasia
| |
| ** [[Ductal carcinoma]] in situ
| |
| * Microinvasive carcinoma
| |
| * Intraductal papillary neoplasms
| |
| ** Central [[papilloma]]
| |
| ** Peripheral papilloma
| |
| ** Atypical papilloma
| |
| ** Intraductal papillary carcinoma
| |
| ** Intracystic papillary carcinoma
| |
| | |
| '''Benign epithelial lesions'''
| |
| * Adenosis, includin variants
| |
| ** Sclerosing adenosis
| |
| ** Apocrine adenosis
| |
| ** Blunt duct adenosis
| |
| ** Microglandular adenosis
| |
| ** Adenomyoepithelial adenosis
| |
| * Radial scar / complex sclerosing lesion
| |
| * Adenomas
| |
| ** Tubular adenoma
| |
| ** Lactating adenoma
| |
| ** Apocrine adenoma
| |
| ** [[Pleomorphic adenoma]]
| |
| ** Ductal adenoma
| |
| | |
| '''Myoepithelial lesions'''
| |
| * Myoepitheliosis
| |
| * Adenomyoepithelial adenosis
| |
| * Adenomyoepithelioma
| |
| * Malignant myoepithelioma
| |
| | |
| '''Fibroepithelial tumours'''
| |
| * [[Fibroadenoma]]
| |
| * [[Phyllodes tumour]]
| |
| ** Benign
| |
| ** Borderline
| |
| ** Malignant
| |
| * Periductal stromal sarcoma, low grade
| |
| * Mammary [[hamartoma]]
| |
| | |
| '''Tumours of the nipple'''
| |
| * Nipple adenoma
| |
| * Syringomatous adenoma
| |
| * [[Paget's disease]] of the nipple
| |
| | |
| '''Malignant [[lymphoma]]'''
| |
| | |
| '''Metastatic tumours'''
| |
| | |
| '''Tumours of the male breast'''
| |
| * [[Gynecomastia]]
| |
| * Carcinoma
| |
| ** In situ
| |
| ** Invasive
| |
| | |
| The classifications above show that breast cancer is usually, but not always, classified by its histological appearance. Rare variants are defined on the basis of [[physical exam]] findings. For example, [[Inflammatory breast cancer]] (IBC), a form of ductal carcinoma or malignant cancer in the ducts, is distinguished from other [[carcinoma]]s by the [[inflammation|inflamed]] appearance of the affected breast.<ref>{{cite journal |author=Giordano SH, Hortobagyi GN |title=Inflammatory breast cancer: clinical progress and the main problems that must be addressed |journal=Breast Cancer Res. |volume=5 |issue=6 |pages=284-8 |year=2003 |pmid=14580242 |doi=10.1186/bcr608}} [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=14580242 Free Full Text].</ref> In the future, some pathologic classifications may be changed. For example, a subset of ductal carcinomas may be re-named [[basal-like carcinoma]] (part of the [[Triple Negative Breast Cancer|"triple-negative" tumors]]).
| |
| | |
| ===Histologic types===
| |
| ====Carcinomas====
| |
| =====in situ=====
| |
| *[[Ductal carcinoma]] (DCIS) 80%
| |
| *Lobular carcinoma (LCIS) 20%
| |
| | |
| =====Invasive=====
| |
| *Carcinoma NOS (not otherwise specified)
| |
| *Lobular carcinoma
| |
| *Tubular/cribriform carcinoma
| |
| *Mucinous (colloid) carcinoma
| |
| *Medullary carcinoma
| |
| *Papillary carcinoma
| |
| *Metaplastic carcinoma
| |
| | |
| ====Sarcomas====
| |
| *[[Phyllodes tumour]]
| |
| | |
| ===Clinical categorizations===
| |
| Breast cancer is occasionally classified clinically (on [[physical exam]] findings, [[medical history|(medical) history]]). [[Inflammatory breast cancer]] (IBC) is an example of a clinically classified breast cancer and can be any histologic type.<ref>{{cite journal |author=Giordano SH, Hortobagyi GN |title=Inflammatory breast cancer: clinical progress and the main problems that must be addressed |journal=Breast Cancer Res. |volume=5 |issue=6 |pages=284-8 |year=2003 |pmid=14580242 |doi=10.1186/bcr608}} [http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=14580242 Free Full Text].</ref>
| |
| | |
| ==Signs and symptoms==
| |
| | |
| Early breast cancer can in some cases present as breast pain ([[mastodynia]]) or a painful lump. Since the advent of breast mammography, breast cancer is most frequently discovered as an asymptomatic nodule on a mammogram, before any symptoms are present. A lump under the arm or above the [[collarbone]] that does not go away may be present. When breast cancer associates with skin [[inflammation]], this is known as inflammatory breast cancer. In inflammatory breast cancer, the breast tumor itself is causing an [[inflammatory]] reaction of the skin, and this can cause pain, swelling, warmth, and redness throughout the breast.
| |
| | |
| Changes in the appearance or shape of the breast can raise suspicions of breast cancer.
| |
| | |
| Another reported symptom complex of breast cancer is [[Paget's disease of the breast]]. This [[syndrome]] presents as eczematoid skin changes at the nipple, and is a late manifestation of an underlying breast cancer.
| |
| | |
| Most breast symptoms do not turn out to represent underlying breast cancer. Benign breast diseases such as fibrocystic mastopathy], [[mastitis]], functional mastodynia, and [[fibroadenoma]] of the breast are more common causes of breast symptoms. The appearance of a new breast symptom should be taken seriously by both patients and their doctors, because of the possibility of an underlying breast cancer at almost any age.
| |
| | |
| Occasionally, breast cancer presents as [[metastatic]] disease, that is, cancer that has spread beyond the original organ. Metastatic breast cancer will cause symptoms that depend on the location of metastasis. More common sites of metastasis include bone, liver, lung, and brain. Unexplained weight loss can occasionally herald an occult breast cancer, as can symptoms of fevers or chills. Bone or joint pains can sometimes be manifestations of metastatic breast cancer, as can jaundice or neurological symptoms. Pleural effusions are not uncommon with [[metastatic]] breast cancer. Obviously, these symptoms are "non-specific," meaning they can also be manifestations of many other illnesses.
| |
| | |
| ==Epidemiology and etiology==
| |
| {{main|Epidemiology and etiology of Breast cancer}}
| |
| [[Epidemiological]] risk factors for a disease can provide important clues as to the [[etiology]] of a disease. The first work on breast cancer epidemiology was done by [[Janet Lane-Claypon]], who published a comparative study in 1926 of 500 breast cancer cases and 500 control patients of the same background and lifestyle for the British Ministry of Health.
| |
| | |
| Today, breast cancer, like other forms of cancer, is considered to be the final outcome of multiple environmental and hereditary factors.
| |
| # Lesions to [[DNA]] such as [[genetic mutations]]. Exposure to estrogen has been experimentally linked to the mutations that cause breast cancer.<ref name="pmid16675129">{{cite journal |author=Cavalieri E, Chakravarti D, Guttenplan J, ''et al'' |title=Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention |journal=Biochim. Biophys. Acta |volume=1766 |issue=1 |pages=63-78 |year=2006 |pmid=16675129 |doi=10.1016/j.bbcan.2006.03.001}}</ref> Beyond the contribution of estrogen, research has implicated viral oncogenesis and the contribution of [[ionizing radiation]].
| |
| # Failure of immune surveillance, which usually removes malignancies at early phases of their natural history.
| |
| # Abnormal [[growth factor]] signaling in the interaction between [[stromal cells]] and [[epithelial cells]], for example in the [[angiogenesis]] necessary to promote new blood vessel growth near new cancers.
| |
| # Inherited defects in [[DNA repair genes]], such as ''BRCA1'', ''BRCA2'' and ''p53''.
| |
| | |
| Although many epidemiological risk factors have been identified, the cause of any individual breast cancer is often unknowable. In other words, epidemiological research informs the patterns of breast cancer incidence across certain populations, but not in a given individual. Approximately 5% of new breast cancers are attributable to hereditary syndromes, while no [[etiology]] is known for the other 95% of cases.<ref name=Madigan_1995>{{cite journal | author = Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN | title = Proportion of breast cancer cases in the United States explained by well-established risk factors | journal = J. Natl. Cancer Inst. | volume = 87 | issue = 22 | pages = 1681-5 | year = 1995 | pmid = 7473816 | doi = | accessdate = 2007-05-26}}</ref>
| |
| | |
| The primary risk factors that have been identified are sex,<ref name="Giordano">{{cite journal | last = Giordano | first = Sharon H | authorlink = | coauthors = Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN | title = Breast carcinoma in men | journal = Cancer | volume = 101 | issue = 1 | pages = 51-57 | publisher =American Cancer Society | date = May 2004 | url= http://www3.interscience.wiley.com/cgi-bin/fulltext/108565241/HTMLSTART | doi = | id = | accessdate = }}</ref> age,<ref>{{cite web | title = Individual Risk Factors| publisher = BreastCancer.org | url = http://www.breastcancer.org/cmn_who_indrisk.html | accessdate = 2007-03-11}}</ref> childbearing, hormones,<ref>{{cite journal |author=Yager JD |coauthors=Davidson NE |title=Estrogen carcinogenesis in breast cancer |journal=New Engl J Med |volume=354 |issue=3 |year=2006 |pages=270-82 |id=PMID 16421368}}</ref> a high-fat diet,<ref>{{cite journal | author = Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. | title = Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study (WINS). | journal =J Natl Cancer Inst | volume =98 | issue =24 | pages =1767-1776 | pmid = 17179478 | url =}}</ref> alcohol intake,<ref name=Boffetta_2006>{{cite journal | last = Boffetta | first = Paolo | coauthors = Hashibe, Mia; La Vecchia, Carlo; Zatonski, Witold; Rehm, Jürgen | title = The burden of cancer attributable to alcohol drinking | journal = International Journal of Cancer | volume = 119 | issue = 4 | pages = 884–887 | publisher = Wiley-Liss, Inc | date = 2006-03-23 | url = http://www3.interscience.wiley.com/cgi-bin/abstract/112550783/ABSTRACT | doi = 10.1002/ijc.21903 | accessdate = 2006-10-09 | pmid=16557583 }}</ref> obesity,<ref>BBC report [http://news.bbc.co.uk/1/hi/health/5171838.stm Weight link to breast cancer risk]</ref> and environmental factors such as tobacco use and radiation.<ref name="acs bc facts 2005-6">{{cite web |author=[[American Cancer Society|ACS]] |year=2005 |title=Breast Cancer Facts & Figures 2005-2006 |url=http://www.cancer.org/downloads/STT/CAFF2005BrFacspdf2005.pdf |accessdate=2007-04-26}}</ref>
| |
| | |
| == Prevention ==
| |
| === Phytoestrogens and soy ===
| |
| [[Phytoestrogens]] such as found in soybeans have been extensively studied in animal and human ''in-vitro'' and epidemiological studies. The literature support the following conclusions:
| |
| # Plant estrogen intake, such as from soy products, in early adolescence may protect against breast cancer later in life.<ref name="pmid17158751">{{cite journal |author=Rice S, Whitehead SA |title=Phytoestrogens and breast cancer--promoters or protectors? |journal=Endocr. Relat. Cancer |volume=13 |issue=4 |pages=995-1015 |year=2006 |pmid=17158751 |doi=10.1677/erc.1.01159}}</ref>
| |
| # Plant estrogen intake later in life is not likely to influence breast cancer incidence either positively or negatively.<ref>Gikas PD, Mokbel K. (2005[http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16526415&query_hl=5&itool=pubmed_docsum Phytoestrogens and the risk of breast cancer: a review of the literature]. Int J Fertil Women's Med.</ref>
| |
| It seems reasonable to conclude that [[soybean]]-based [[phytoestrogens]] are not a major contributor to the incidence of breast cancer.
| |
| | |
| === Folic acid (folate) ===
| |
| {{main|Folic acid#Folic acid and cancer}}
| |
| Studies have found that "folate intake counteracts breast cancer risk associated with alcohol consumption"<ref>Mayo Clinic news release [[June 26]] 2001 [http://www.mayoclinic.org/news2001-rst/857.html "Folate Intake Counteracts Breast Cancer Risk Associated with Alcohol Consumption"]</ref> and "women who drink alcohol and have a high folate intake are not at increased risk of cancer."<ref>Boston University,[http://www.bu.edu/act/alcoholandhealth/issues/issue_may04/html/04-0506-ellison_baily.html ''Folate, Alcohol, and Cancer Risk'']</ref><ref>Bailey, L.B. Folate, methyl-related nutrients, alcohol and the MTHFR 677C -> T polymorphous affect cancer risk: intake recommendations. Journal of Nutrition, 2003, 133, 37485-37535</ref><ref name="Zhang_1999">{{cite journal |author=Zhang S, Hunter D, Hankinson S, Giovannucci E, Rosner B, Colditz G, Speizer F, Willett W |title=A prospective study of folate intake and the risk of breast cancer |journal=JAMA |volume=281 |issue=17 |pages=1632-7 |year=1999 |pmid=10235158}}</ref> A prospective study of over 17,000 women found that those who consume 40 grams of alcohol (about 3-4 drinks) per day have a higher risk of breast cancer. However, in women who take 200 micrograms of folate (folic acid or Vitamin B9) every day, the risk of breast cancer drops below that of alcohol abstainers.<ref> Baglietto, Laura, et al. Does dietary folate intake modify effect of alcohol consumption on breast cancer risk? Prospective cohort study. British Medical Journal, August 8, 2005 </ref>
| |
| | |
| Folate is involved in the synthesis, repair, and functioning of [[DNA]], the body’s genetic map, and a deficiency of folate may result in damage to DNA that may lead to cancer.<ref name="Oldref_43">{{cite journal | author=Jennings E. | title=Folic acid as a cancer preventing agent | journal=Medical Hypotheses | volume=45 | issue=3 | year=1995 | pages=297-303 | id=PMID 8569555}}</ref> In addition to breast cancer, studies have also associated diets low in folate with increased risk of [[pancreatic cancer|pancreatic]], and [[colon cancer]].<ref name="Oldref_45">{{cite journal | author=Giovannucci E, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC. | title=Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study | journal=Annals of Internal Medicine | volume=129 | issue=7 | year=1998 | pages=517-524 | id=PMID 9758570}}</ref><ref> name="Oldref_42">{{cite journal | author=Freudenheim JL, Grahm S, Marshall JR, Haughey BP, Cholewinski S, Wilkinson G | title=Folate intake and carcinogenesis of the colon and rectum | journal=International Journal of Epidemiology | volume=20 | issue=2 | year=1991 | pages=368-374 | id=PMID 1917236}}</ref>
| |
| | |
| Foods rich in folate include citrus fruits, citrus juices, dark green leafy vegetables (such as spinach), dried beans, and peas. Vitamin B9 can also be taken in a multivitamin pill.
| |
| | |
| ===Oophorectomy and mastectomy===
| |
| Prophylactic [[oophorectomy]] (removal of ovaries), in high-risk individuals, when child-bearing is complete, reduces the risk of developing breast cancer by 60%, as well as reducing the risk of developing ovarian cancer by 96%.<ref name=Kauff_2002>{{cite journal |author=Kauff N, Satagopan J, Robson M, Scheuer L, Hensley M, Hudis C, Ellis N, Boyd J, Borgen P, Barakat R, Norton L, Castiel M, Nafa K, Offit K |title=Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation |journal=N Engl J Med |volume=346 |issue=21 |pages=1609-15 |year=2002 |url=http://content.nejm.org/cgi/content/abstract/NEJMoa020119v1 |pmid=12023992}}</ref>
| |
| | |
| Bilateral prophylactic [[Mastectomy|mastectomies]] have been shown to prevent breast cancer in high-risk individuals, such as patients with [[BRCA1]] or [[BRCA2]] gene mutations.
| |
| | |
| ===Medications===
| |
| [[Hormonal therapy (oncology)|Hormonal therapy]] has been used for chemoprevention in individuals at high risk for breast cancer. In 2002, a [[clinical practice guideline]] by the US Preventive Services Task Force (USPSTF) recommended that "clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention" with a grade B recommendation.<ref name='USPSTF Ratings'> {{cite web|url=http://www.ahrq.gov/clinic/3rduspstf/ratings.htm |title=Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003 |accessdate=2007-10-07 |work=Agency for Healthcare Research and Quality |publisher=[[US Preventive Services Task Force]] }}</ref><ref name="pmid12093249">{{cite journal |author= |title=Chemoprevention of breast cancer: recommendations and rationale |journal=Ann. Intern. Med. |volume=137 |issue=1 |pages=56-8 |year=2002 |pmid=12093249 |doi=|url=http://www.annals.org/cgi/content/full/137/1/56}}</ref><ref name="pmid12093250">{{cite journal |author=Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN |title=Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force |journal=Ann. Intern. Med. |volume=137 |issue=1 |pages=59-69 |year=2002 |url=http://www.annals.org/cgi/content/full/137/1/59|pmid=12093250 |doi=}}</ref>
| |
| | |
| ====Selective estrogen receptor modulators (SERMs)====
| |
| The guidelines were based on studies of [[SERM]]s from the MORE, BCPT P-1, and Italian trials. In the MORE trial, the [[relative risk reduction]] for [[raloxifene]] was 76%.<ref name="pmid10376571">{{cite journal |author=Cummings SR, Eckert S, Krueger KA, ''et al'' |title=The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation |journal=JAMA |volume=281 |issue=23 |pages=2189-97 |year=1999 |pmid=10376571 |doi=}}</ref> The P-1 preventative study demonstrated that [[tamoxifen]] can prevent breast cancer in high-risk individuals. The [[relative risk reduction]] was up to 50% of new breast cancers, though the cancers prevented were more likely estrogen-receptor positive (this is analogous to the effect of [[finasteride]] on the prevention of [[prostate cancer]], in which only low-grade [[prostate cancer]]s were prevented).<ref name="pmid16288118">{{cite journal |author=Fisher B, Costantino JP, Wickerham DL, ''et al'' |title=Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study |journal=J. Natl. Cancer Inst. |volume=97 |issue=22 |pages=1652-62 |year=2005 |pmid=16288118 |doi=10.1093/jnci/dji372}}</ref><ref name="pmid9747868">{{cite journal |author=Fisher B, Costantino JP, Wickerham DL, ''et al'' |title=Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study |journal=J. Natl. Cancer Inst. |volume=90 |issue=18 |pages=1371-88 |year=1998 |pmid=9747868 |doi=}}</ref> The Italian trial showed benefit from tamoxifen.<ref name="pmid17470740">{{cite journal |author=Veronesi U, Maisonneuve P, Rotmensz N, ''et al'' |title=Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy |journal=J. Natl. Cancer Inst. |volume=99 |issue=9 |pages=727-37 |year=2007 |pmid=17470740 |doi=10.1093/jnci/djk154}}</ref>
| |
| | |
| Additional [[randomized controlled trials]] have been published since the guidelines. The IBIS trial found benefit from [[tamoxifen]].<ref name="pmid17312304">{{cite journal |author=Cuzick J, Forbes JF, Sestak I, ''et al'' |title=Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial |journal=J. Natl. Cancer Inst. |volume=99 |issue=4 |pages=272-82 |year=2007 |pmid=17312304 |doi=10.1093/jnci/djk049}}</ref> In 2006, the NSABP STAR trial demonstrated that [[raloxifene]] had equal efficacy in preventing breast cancer compared with [[tamoxifen]], but that there were fewer side effects with [[raloxifene]].<ref name="pmid16754727">{{cite journal |author=Vogel VG, Costantino JP, Wickerham DL, ''et al'' |title=Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial |journal=JAMA |volume=295 |issue=23 |pages=2727-41 |year=2006 |pmid=16754727 |doi=10.1001/jama.295.23.joc60074}}</ref> The RUTH Trial concluded that "benefits of raloxifene in reducing the risks of invasive breast cancer and vertebral fracture should be weighed against the increased risks of venous thromboembolism and fatal stroke".<ref name="pmid16837676">{{cite journal |author=Barrett-Connor E, Mosca L, Collins P, ''et al'' Raloxifene Use for The Heart (RUTH) Trial Investigators. |title=Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women |journal=N. Engl. J. Med. |volume=355 |issue=2 |pages=125-37 |year=2006 |pmid=16837676 |doi=10.1056/NEJMoa062462}}</ref> On September 14, 2007, Steven Galson, director, US Food and Drug Administration's [[Center for Drug Evaluation and Research]] announced approval of the sale of raloxifene to prevent invasive breast cancer in postmenopausal women.<ref>[http://afp.google.com/article/ALeqM5iN5TpHWbHfPZMBgXvaIyVlgc-XZQ AFP.google.com, US approves Lilly's Evista for breast cancer prevention]</ref>
| |
| | |
| ==Screening==
| |
| {{main|Breast cancer screening}}
| |
| | |
| Breast cancer screening is an attempt to find unsuspected cancers. The most common screening methods are self and clinical breast exams, x-ray [[mammography]], Breast [[Magnetic resonance imaging]] (MRI), ultrasound, and genetic testing.
| |
| | |
| ===X-ray mammography===
| |
| Mammography is still the modality of choice for screening of early breast cancer, since it is relatively fast, reasonably accurate, and widely available in developed countries. Breast cancers detected by mammography are usually much smaller (earlier stage) than those detected by patients or doctors as a breast lump.
| |
| | |
| Due to the high incidence of breast cancer among older women, screening is now recommended in many countries. Recommended screening methods include [[breast self-examination]] and [[mammography]]. Mammography has been estimated to reduce breast cancer-related mortality by 20-30%.<ref>{{cite journal | author = Elwood J, Cox B, Richardson A | title = The effectiveness of breast cancer screening by mammography in younger women. | journal = Online J Curr Clin Trials | volume = Doc No 32 | issue = | pages = [23,227 words; 195 paragraphs] | year = | id = PMID 8305999}}</ref> Routine (annual) mammography of women older than age 40 or 50 is recommended by numerous organizations as a screening method to diagnose early breast cancer and has demonstrated a protective effect in multiple clinical trials.<ref>{{cite journal | author = Fletcher S, Black W, Harris R, Rimer B, Shapiro S | title = Report of the International Workshop on Screening for Breast Cancer. | journal = J Natl Cancer Inst | volume = 85 | issue = 20 | pages = 1644-56 | year = 1993 | id = PMID 8105098}}</ref> The evidence in favor of mammographic screening comes from eight randomized clinical trials from the 1960s through 1980s. Many of these trials have been criticised for methodological errors, and the results were summarized in a review article published in 1993.<ref name=Fletcher_1993>{{cite journal | author = Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S | title = Report of the International Workshop on Screening for Breast Cancer | journal = J. Natl. Cancer Inst. | volume = 85 | issue = 20 | pages = 1644-56 | year = 1993 | pmid = 8105098 | doi = | accessdate = 2007-05-26}}</ref>
| |
| | |
| Improvements in mortality due to screening are hard to measure; similar difficulty exists in measuring the impact of [[Pap smear]] testing on [[cervical cancer]], though worldwide, the impact of that test is likely enormous. Nationwide mortality due to cancer before and after the institution of a screening test is a surrogate indicator about the effectiveness of screening, and results of mammography are favorable.
| |
| | |
| [[Image:Mammo breast cancer.jpg|thumb|right|Normal (left) versus cancerous (right) mammography image.]]
| |
|
| |
|
| The U.S. [[National Cancer Institute]] recommends screening mammography every one to two years beginning at age 40.<ref name="NCI_MMG_Screening">{{cite web |url=http://www.cancer.gov/newscenter/mammstatement31jan02 |title=NCI Statement on Mammography Screening - National Cancer Institute |accessdate=2007-09-11 |format= |work=}}</ref> In the UK, women are invited for screening once every three years beginning at age 50. Women with one or more first-degree relatives (mother, sister, daughter) with premenopausal breast cancer should begin screening at an earlier age. It is usually suggested to start screening at an age that is 10 years less than the age at which the relative was diagnosed with breast cancer.
| | ==[[Breast cancer historical perspective|Historical Perspective]]== |
|
| |
|
| A [[clinical practice guideline]] by the US Preventive Services Task Force recommended "screening mammography, with or without clinical breast examination (CBE), every 1 to 2 years for women aged 40 and older."<ref name="pmid12204019">{{cite journal |author= |title=Screening for breast cancer: recommendations and rationale |journal=Ann. Intern. Med. |volume=137 |issue=5 Part 1 |pages=344-6 |year=2002 |pmid=12204019 |doi=|url=http://www.annals.org/cgi/content/full/137/5_Part_1/344}}</ref> The Task Force gave a grade B recommendation.<ref name='USPSTF Ratings'/>
| | ==[[Breast cancer classification|Classification]]== |
|
| |
|
| ===Criticisms of screening mammography=== | | ==[[Breast cancer pathophysiology|Pathophysiology]]== |
| Several scientific groups however have expressed concern about the public's perceptions of the benefits of breast screening.<ref>{{cite news | first= | last= | coauthors= | title=Women 'misjudge screening benefits' | date= Monday, 15 October, 2001 | publisher= | url =http://news.bbc.co.uk/1/hi/health/1601267.stm | work =BBC | pages = | accessdate = 2007-04-04 | language = }}</ref> In 2001, a controversial review published in [[The Lancet]] claimed that ''there is no reliable evidence that screening for breast cancer reduces mortality''.<ref>{{cite journal |author=Olsen O, Gøtzsche P |title=Cochrane review on screening for breast cancer with mammography |journal=Lancet |volume=358 |issue=9290 |pages=1340-2 |year=2001 |pmid=11684218}}</ref> The results of this study were widely reported in the popular press.<ref>{{cite news | first= | last= | coauthors= | title=New concerns over breast screening | date= Thursday, 18 October, 2001 | publisher= | url =http://news.bbc.co.uk/1/hi/health/1607113.stm | work =BBC | pages = | accessdate = 2007-04-04 | language = }}</ref>
| |
|
| |
|
| False positives are a major problem of mammographic breast cancer screening. Data reported in the UK Million Woman Study indicates that if 134 mammograms are performed, 20 women will be called back for suspicious findings, and four biopsies will be necessary, to diagnose one cancer. Recall rates are higher in the U.S. than in the UK.<ref name="pmid15814020">{{cite journal |author=Smith-Bindman R, Ballard-Barbash R, Miglioretti DL, Patnick J, Kerlikowske K |title=Comparing the performance of mammography screening in the USA and the UK |journal=Journal of medical screening |volume=12 |issue=1 |pages=50-4 |year=2005 |pmid=15814020 |doi=10.1258/0969141053279130}}</ref> The contribution of mammography to the early diagnosis of cancer is controversial, and for those found with benign lesions, mammography can create a high psychological and financial cost.
| | ==[[Breast cancer causes|Causes]]== |
|
| |
|
| ====Mammography in women less than 50 years old==== | | ==[[Breast cancer differential diagnosis|Differentiating Breast Cancer from other Diseases]]== |
| Part of the difficulty in interpreting mammograms in younger women stems from the problem of breast density. Radiographically, a dense breast has a preponderance of glandular tissue, and younger age or [[estrogen]] [[hormone replacement therapy]] contribute to mammographic breast density. After menopause, the breast glandular tissue gradually is replaced by fatty tissue, making mammographic interpretation much more accurate. Some authors speculate that part of the contribution of [[estrogen]] [[hormone replacement therapy]] to breast cancer mortality arises from the issue of increased mammographic breast density. Breast density is an independent adverse prognostic factor on breast cancer prognosis.
| |
|
| |
|
| A [[systematic review]] by the [[American College of Physicians]] concluded "Although few women 50 years of age or older have risks from mammography that outweigh the benefits, the evidence suggests that more women 40 to 49 years of age have such risks".<ref name="pmid17404354">{{cite journal |author=Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE |title=Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians |journal=Ann. Intern. Med. |volume=146 |issue=7 |pages=516-26 |year=2007 |pmid=17404354 |doi=}}</ref>
| | ==[[Breast cancer epidemiology and demographics|Epidemiology and Demographics]]== |
|
| |
|
| ===Enhancements to mammography=== | | ==[[Breast cancer risk factors|Risk factors]]== |
| In general, digital mammography and computer-aided mammography have increased the sensitivity of mammograms, but at the cost of more numerous false positive results.
| |
|
| |
|
| [[Computer-aided diagnosis]](CAD) Systems may help radiologists to evaluate X-ray images to detect breast cancer in an early stage. CAD is especially established in US and the Netherlands. It is used in addition to the human evaluation of the diagnostician. | | ==[[Breast cancer screening|Screening]]== |
| | [[Breast cancer screening#X-ray mammography|X Ray Mammography]] | [[Breast cancer screening#Breast MRI|Breast MRI]] | [[Breast cancer screening#Breast ultrasound|Breast Ultrasound]] | [[Breast cancer screening#Breast self-exam|Self Exam]] | [[Breast cancer screening#Genetic testing|Genetic Testing]] |
|
| |
|
| ===Breast MRI=== | | ==[[Breast cancer natural history|Natural History, Complications and Prognosis]]== |
| [[Magnetic resonance imaging]] (MRI) has been shown to detect cancers not visible on mammograms, but has long been regarded to have disadvantages. For example, although it is 27-36% more sensitive, it is less specific than mammography.<ref>{{cite journal | author = Hrung J, Sonnad S, Schwartz J, Langlotz C | title = Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis. | journal = Acad Radiol | volume = 6 | issue = 7 | pages = 387-97 | year = 1999 | id = PMID 10410164}}</ref> As a result, MRI studies will have more [[Type I and type II errors|false positives]] (up to 5%), which may have undesirable financial and psychological costs. It is also a relatively expensive procedure, and one which requires the intravenous injection of a chemical agent to be effective. | |
| Proposed indications for using MRI for screening include:<ref>{{cite journal | author = Morrow M | title = Magnetic resonance imaging in breast cancer: one step forward, two steps back? | journal = JAMA | volume = 292 | issue = 22 | pages = 2779-80 | year = 2004 | id = PMID 15585740}}</ref>
| |
| *Strong family history of breast cancer
| |
| *Patients with BRCA-1 or BRCA-2 oncogene mutations
| |
| *Evaluation of women with breast implants
| |
| *History of previous lumpectomy or breast biopsy surgeries
| |
| *Axillary metastasis with an unknown primary tumor
| |
| *Very dense or scarred breast tissue
| |
| | |
| However, two studies published in 2007 demonstrated the strengths of [[MRI]]-based screening:
| |
| | |
| *In March 2007, an article published in the ''[[New England Journal of Medicine]]'' demonstrated that in 3.1% of patients with breast cancer, whose [[contralateral]] breast was clinically and mammographically tumor-free, [[MRI]] could detect breast cancer. [[Sensitivity (tests)|Sensitivity]] for detection of breast cancer in this study was 91%, [[Specificity (tests)|specificity]] 88%.<ref>{{cite journal | author = Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB, DePeri ER, Bluemke DA, Schnall MD | title = MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.| journal = N Engl J Med.| volume = 356 | issue = 13| pages = 1295-1303| year = 2007 | id = PMID 17392300}}</ref>
| |
| | |
| *In August 2007, an article published in ''[[The Lancet]]'' compared [[MRI]] breast cancer screening to conventional mammographic screening in 7,319 women. [[MRI]] screening was highly more sensitive (97% in the MRI group vs. 56% in the mammography group) in recognizing early high-grade [[Carcinoma in situ| Ductal Carcinoma in situ (DCIS)]], the most important precursor of invasive carcinoma. Despite the high [[Sensitivity (tests)|sensitivity]], MRI screening had a [[positive predictive value]] of 52%, which is totally accepted for cancer screening tests.<ref>{{cite journal | author = Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Kuhn W, Schild HH| title = MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study| journal = The Lancet | volume = 370 | issue = 9586 | pages = 485-492 | year = 2007 | id = PMID }}</ref> The author of a comment published in the same issue of ''The Lancet'' concludes that "MRI outperforms mammography in tumour detection and diagnosis."<ref>{{cite journal | author = Boetes C, Mann RM| title = Ductal carcinoma in situ and breast MRI| journal = The Lancet | volume = 370 | issue = 9586 | pages = 459-460 | year = 2007 | id = PMID }}</ref>
| |
| | |
| ===Breast ultrasound===
| |
| | |
| [[Medical ultrasonography|Ultrasound]] alone is not usually employed as a screening tool but it is a useful additional tool for the characterization of palpable tumours and directing image-guided biopsies. U-Systems is a US-based company that is selling a breast-cancer detection system using ultrasound that is fully-automated. Using an ultrasound allows a look at dense breast tissue which is not possible with digital mammmography. It is closely correlated with the digital mammography. The other significant advantage over digital mammography is that it is a pain-free procedure.
| |
| | |
| ===Breast self-exam===
| |
| [[Breast self-examination]] was widely discussed in the 1990s as a useful modality for detecting breast cancer at an earlier stage of presentation. A large clinical trial in China reduced enthusiasm for breast self-exam. In the trial, reported in the ''Journal of the National Cancer Institute'' first in 1997 and updated in 2002, 132,979 female Chinese factory workers were taught by nurses at their factories to perform monthly breast self-exam, while 133,085 other workers were not taught self-exam. The women taught self-exam tended to detect more breast nodules, but their breast cancer mortality rate was no different from that of women in the control group. In other words, women taught breast self-exam were mostly likely to detect benign breast disease, but were just as likely to die of breast cancer.<ref name="pmid12359854">{{cite journal |author=Thomas DB, Gao DL, Ray RM, ''et al'' |title=Randomized trial of breast self-examination in Shanghai: final results |journal=J. Natl. Cancer Inst. |volume=94 |issue=19 |pages=1445-57 |year=2002 |pmid=12359854 |doi=}}</ref> An editorial in the Journal of the National Cancer Institute reported in 2002, "Routinely Teaching Breast Self-Examination is Dead. What Does This Mean?"<ref name="pmid12359843">{{cite journal |author=Harris R, Kinsinger LS |title=Routinely teaching breast self-examination is dead. What does this mean? |journal=J. Natl. Cancer Inst. |volume=94 |issue=19 |pages=1420-1 |year=2002 |pmid=12359843 |doi=}}</ref>
| |
| | |
| ===Genetic testing===
| |
| A [[clinical practice guideline]] by the US Preventive Services Task Force :<ref name="pmid12204019">{{cite journal |author= |title=Screening for breast cancer: recommendations and rationale |journal=Ann. Intern. Med. |volume=137 |issue=5 Part 1 |pages=344-6 |year=2002 |pmid=12204019 |doi=|url=http://www.annals.org/cgi/content/full/137/5_Part_1/344}}</ref>
| |
| * "recommends against routine referral for [[genetic counseling]] or routine breast cancer susceptibility gene (BRCA) testing for women whose family history is not associated with an increased risk for deleterious mutations in breast cancer susceptibility gene 1 ([[BRCA1]]) or breast cancer susceptibility gene 2 ([[BRCA2]])" The Task Force gave a grade D recommendation.<ref name='USPSTF Ratings'/>
| |
| *"recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing." The Task Force gave a grade B recommendation.<ref name='USPSTF Ratings'/>
| |
| | |
| The Task Force noted that about 2% of women have family histories that indicate increased risk as defined by:
| |
| * For non–Ashkenazi Jewish women, any of the following:
| |
| ** "2 first-degree relatives with breast cancer, 1 of whom received the diagnosis at age 50 years or younger"
| |
| ** "3 or more first- or second-degree relatives with breast cancer regardless of age at diagnosis"
| |
| ** "both breast and ovarian cancer among first- and second- degree relatives"
| |
| ** "a first-degree relative with bilateral breast cancer"
| |
| ** "a combination of 2 or more first- or second-degree relatives with ovarian cancer regardless of age at diagnosis"
| |
| ** "a first- or second-degree relative with both breast and ovarian cancer at any age"
| |
| ** "a history of breast cancer in a male relative."
| |
| *"For women of Ashkenazi Jewish heritage, an increased-risk family history includes any first-degree relative (or 2 second-degree relatives on the same side of the family) with breast or ovarian cancer."
| |
|
| |
|
| ==Diagnosis== | | ==Diagnosis== |
| | [[Breast cancer diagnostic study of choice|Diagnostic Study of Choice]]| [[Breast Biopsy]]|[[Breast cancer history and symptoms| History and Symptoms]] | [[Breast cancer physical examination | Physical Examination]] |[[Breast cancer laboratory tests | Laboratory Findings]] | Electrocardiogram| [[Breast cancer chest x ray|X Ray]] | [[Breast cancer CT|CT]] scan| [[Breast cancer MRI|MRI]] | [[Breast cancer echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Breast cancer other imaging studies|Other Imaging Studies]] | [[Breast cancer other diagnostic studies|Other Diagnostic Studies]] |
| | |
|
| |
|
| Breast cancer is diagnosed by the examination of surgically removed breast tissue. A number of procedures can obtain tissue or cells prior to definitive treatment for histological or cytological examination. Such procedures include fine-needle aspiration, nipple aspirates, ductal lavage, core needle biopsy, and local surgical excision. These diagnostic steps, when coupled with radiographic imaging, are usually accurate in diagnosing a breast lesion as cancer. Occasionally, pre-surgical procedures such as fine needle aspirate may not yield enough tissue to make a diagnosis, or may miss the cancer entirely. Imaging tests are sometimes used to detect [[metastasis]] and include [[chest X-ray]], [[bone scan]], [[Cat scan]], [[MRI]], and [[Positron emission tomography|PET]] scanning. While imaging studies are useful in determining the presence of metastatic disease, they are not in and of themselves diagnostic of cancer. Only microscopic evaluation of a biopsy specimen can yield a cancer diagnosis. Ca 15.3 (carbohydrate antigen 15.3, epithelial mucin) is a [[tumor marker]] determined in blood which can be used to follow disease activity over time after definitive treatment. Blood tumor marker testing is not routinely performed for the screening of breast cancer, and has poor performance characteristics for this purpose.
| |
|
| |
| ==Staging==
| |
|
| |
| Breast cancer is [[Cancer staging|staged]] according to the TNM system, updated in the American Joint Committee on Cancer (AJCC) Staging Manual, now on its sixth edition. Prognosis is closely linked to results of staging, and staging is also used to allocate patients to treatments both in clinical trials and clinical practice.
| |
|
| |
| '''Summary of stages:'''
| |
| * ''Stage 0'' - [[Carcinoma in situ]]
| |
| * ''Stage I'' - Tumor (T) does not involve axillary lymph nodes (N).
| |
| * ''Stage IIA'' – T 2-5 cm, N negative, or T <2 cm and N positive.
| |
| * ''Stage IIB'' – T > 5 cm, N negative, or T 2-5 cm and N positive (< 4 axillary nodes).
| |
| * ''Stage IIIA'' – T > 5 cm, N positive, or T 2-5 cm with 4 or more axillary nodes
| |
| * ''Stage IIIB'' – T has penetrated chest wall or skin, and may have spread to < 10 axillary N
| |
| * ''Stage IIIC'' – T has > 10 axillary N, 1 or more supraclavicular or infraclavicular N, or internal mammary N.
| |
| * ''Stage IV'' – Distant metastasis (M)
| |
|
| |
| Breast lesions are examined for certain markers, notably sex steroid hormone receptors.
| |
| About two thirds of postmenopausal breast cancers are [[estrogen receptor]] positive (ER+) and [[progesterone receptor]] positive (PR+).<ref>Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status. Cancer Detect Prev 2005;29:419-26</ref> Receptor status modifies the treatment as, for instance, only ER-positive tumors, not ER-negative tumors, are sensitive to hormonal therapy.
| |
|
| |
|
| The breast cancer is also usually tested for the presence of human epidermal growth factor receptor 2, a protein also known as HER2, neu or erbB2. HER2 is a cell-surface protein involved in cell development. In normal cells, HER2 controls aspects of cell growth and division. When activated in cancer cells, HER2 accelerates tumor formation. About 20-30% of breast cancers overexpress HER2. Those patients may be candidates for the drug [[trastuzumab]], both in the postsurgical setting (so-called "[[adjuvant]]" therapy), and in the metastatic setting.<ref>[http://www.cancer.gov/cancertopics/factsheet/therapy/herceptin, accessed 1/30/07 cancer.gov]</ref>
| | ==[[Breast cancer treatment|Treatment]]== |
| | [[Breast cancer Medical therapy|Medical Therapy]]| [[Breast cancer Surgery|Surgery]] | [[Breast cancer bone metastasis|Bone Metastasis]]| [[Breast cancer primary prevention|Primary Prevention]] | [[Breast cancer cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Breast cancer future or investigational therapies|Future or Investigational Therapies]] |
|
| |
|
| ==Treatment== | | ==Case Studies== |
| {{main|Breast cancer treatment}}
| | [[Breast cancer case study one|Case #1]] |
| The mainstay of breast cancer treatment is [[surgery]] when the tumor is localized, with possible adjuvant hormonal therapy (with [[tamoxifen]] or an [[aromatase inhibitor]]), [[chemotherapy]], and/or [[radiotherapy]]. At present, the treatment recommendations after surgery (adjuvant therapy) follow a pattern. This pattern is subject to change, as every two years, a worldwide conference takes place in St. Gallen, Switzerland, to discuss the actual results of worldwide multi-center studies. Depending on clinical criteria (age, type of cancer, size, metastasis) patients are roughly divided to high risk and low risk cases, with each risk category following different rules for therapy. Treatment possibilities include radiation therapy, chemotherapy, hormone therapy, and immune therapy.
| |
| | |
| In planning treatment, doctors can also use PCR tests like [[Oncotype DX]] or [[microarray]] tests like [[MammaPrint]] that predict breast cancer recurrence risk based on gene expression. In February 2007, the MammaPrint test became the first breast cancer predictor to win formal approval from the [[Food and Drug Administration]]. This is a new gene test to help predict whether women with early-stage breast cancer will relapse in 5 or 10 years, this could help influence how aggressively the initial tumor is treated.<ref name="NewsMax">"[http://newsmax.com/archives/articles/2007/2/6/130740.shtml FDA Approves New Breast Cancer Test]". Associated Press, February 6, 2007.</ref>
| |
| | |
| ==Prognosis==
| |
| | |
| There are several prognostic factors associated with breast cancer. [[Cancer staging|Stage]] is the most important, as it takes into consideration local involvement, lymph node status and whether metastatic disease is present. The higher the stage at diagnosis, the worse the prognosis. Breast cancer patients whose lymph nodes are cancer-free have a much better prognosis than those whose lymph nodes are positive for cancer.
| |
| | |
| The presence of estrogen and progesterone receptors in the cancer cell is another important prognostic factor which may guide treatment. Hormone receptor positive breast cancer is usually associated with much better prognosis compared to hormone negative breast cancer.
| |
| | |
| [[HER2/neu]] status has also been described as a prognostic factor. Patients whose cancer cells are positive for HER2/neu have more aggressive disease and may be treated with [[trastuzumab]], a [[monoclonal antibody]] that targets this protein.
| |
| | |
| ===Psychological aspects of diagnosis and treatment===
| |
| The emotional impact of cancer diagnosis, symptoms, treatment, and related issues can be severe. Most larger hospitals are associated with [[cancer support group]]s which can help patients cope with the many issues that come up in a supportive environment with other people with experience with similar issues. Online [[cancer support group]]s are also very beneficial to cancer patients, especially in dealing with uncertainty and body-image problems inherent in cancer treatment.
| |
| | |
| ==Metastasis==
| |
| Most people understand breast cancer as something that happens in the breast. However it can [[metastasis]]e (spread) via lymphatics to nearby lymph nodes, usually those under the arm. That is why surgery for breast cancer always involves some type of surgery for the glands under the arm — either axillary clearance, sampling, or sentinel node biopsy.
| |
| | |
| Breast cancer can also spread to other parts of the body via blood vessels. So it can spread to the lungs, pleura (the lining of the lungs), liver, brain, and most commonly to the bones. Seventy percent of the time that breast cancer spreads to other locations, it spreads to bone, especially the vertebrae and the long bones of the arms, legs, and ribs. Breast cancer cells "set up house" in the bones and form tumors. Usually when breast cancer spreads to bone, it eats away healthy bone, causing weak spots, where the bones can break easily. That is why breast cancer patients are often seen wearing braces or using a wheelchair, and why they complain about aching bones.
| |
| | |
| When breast cancer is found in bones, it has usually spread to more than one site. At this stage, it is treatable, often for many years, but it is not curable. Like normal breast cells, these tumors in the bone often thrive on female hormones, especially estrogen. Therefore, the doctor often treats the patient with medicines that lower her estrogen levels.
| |
| | |
| ==History==
| |
| Breast cancer may be one of the oldest known forms of cancer tumors in humans. The oldest description of cancer (although the term cancer was not used) was discovered in Egypt and dates back to approximately 1600 BC. The Edwin Smith Papyrus describes 8 cases of tumors or ulcers of the breast that were treated by [[cauterization]].The writing says about the disease, "There is no treatment."<ref>{{cite web
| |
| | title = The History of Cancer
| |
| | work = [[American Cancer Society]]
| |
| | date = 2002-03-25
| |
| | url = http://www.cancer.org/docroot/CRI/content/CRI_2_6x_the_history_of_cancer_72.asp?sitearea=CRI
| |
| | accessdate = 2006-10-09 }}</ref> For centuries, physicians described similar cases in their practises, with the same sad conclusion. It wasn't until doctors achieved greater understanding of the circulatory system in the 17th century that they could establish a link between breast cancer and the [[lymph nodes]] in the armpit. The French surgeon [[Jean Louis Petit]] (1674-1750) and later the Scottish surgeon [[Benjamin Bell]] (1749-1806) were the first to remove the lymph nodes, breast tissue, and underlying chest muscle. Their successful work was carried on by [[William Stewart Halsted]] who started performing [[radical mastectomy|mastectomies]] in 1882. He became known for his [[radical mastectomy|Halsted radical mastectomy]], a surgical procedure that remained popular up to the 1970s.
| |
| | |
| ==Cultural references==
| |
| | |
| [[Image:Pink ribbon.svg| 80px | right]]
| |
| In the month of October, breast cancer is recognized by survivors, family and friends of survivors and/or victims of the disease. A pink ribbon is worn to recognize the struggle that sufferers face when battling the cancer.
| |
| | |
| Pink for October is an initiative started by Matthew Oliphant, which asks that any sites willing to help make people aware of breast cancer, change their template or layout to include the color pink, so that when visitors view the site, they see that the majority of the site is pink. Then after reading a short amount of information about breast cancer, or being redirected to another site, they are aware of the disease itself.
| |
| | |
| The patron saint of breast cancer is Saint Agatha of Sicily.
| |
|
| |
|
| ==Related Chapters== | | ==Related Chapters== |
| <div style="-moz-column-count:2; column-count:2;"> | | <div style="-moz-column-count:2; column-count:2;"> |
| *[[List of breast carcinogenic substances]] | | *[[List of breast carcinogenic substances]] |
| *[[Mammary tumor]] for breast cancer in other animals
| |
| *[[Breast reconstruction]] | | *[[Breast reconstruction]] |
| *[[Alcohol and cancer]] | | *[[Alcohol and cancer]] |
| *[[Mammography Quality Standards Act]] | | *[[Mammography Quality Standards Act]] |
| *National Breast Cancer Coalition
| |
| *[[National Comprehensive Cancer Network]] | | *[[National Comprehensive Cancer Network]] |
| *[[Breast Cancer Action]] | | *[[Breast Cancer Action]] |
| Line 388: |
Line 54: |
| *[[Susan G. Komen for the Cure]] | | *[[Susan G. Komen for the Cure]] |
| </div> | | </div> |
|
| |
| ==References==
| |
| <!-- ---------------------------------------------------------------
| |
| See http://en.wikipedia.org/wiki/Wikipedia:Footnotes for a
| |
| discussion of different citation methods and how to generate
| |
| footnotes using the <ref> & </ref> tags and the {{Reflist}} template
| |
| -------------------------------------------------------------------- -->
| |
|
| |
| {{Reflist|2}}
| |
|
| |
|
| ==External links== <!-- Before adding links, make sure they meet the requirements as noted in [[WP:EL]] or they may be removed. --> | | ==External links== <!-- Before adding links, make sure they meet the requirements as noted in [[WP:EL]] or they may be removed. --> |
| Line 415: |
Line 72: |
| * [http://www.cancer.org/docroot/LRN/LRN_0.asp?dt=5 American Cancer Society - Learn About Breast Cancer Page] | | * [http://www.cancer.org/docroot/LRN/LRN_0.asp?dt=5 American Cancer Society - Learn About Breast Cancer Page] |
| * [http://www.cancer.gov/cancertopics/types/breast National Cancer Institute: Breast Cancer] | | * [http://www.cancer.gov/cancertopics/types/breast National Cancer Institute: Breast Cancer] |
| * [http://www.imaginis.com Imaginis -Award winning Breast Cancer site]
| |
|
| |
| ===Research and statistics===
| |
| * [http://www.emaxhealth.com/98/ eMaxHealth Breast Cancer] Publishes Research News on Breast Cancer from Research Institutions and Universities
| |
|
| |
|
| ===Clinical=== | | ===Clinical=== |
| * [http://www.radiologyinfo.org/en/info.cfm?pg=breastcancer RadiologyInfo] - The radiology information resource for patients: Breast Cancer
| |
| * [http://www.center4research.org/pdf/booklet04bc.pdf Surgery Choices for Women with Early-Stage Breast Cancer, National Cancer Institute] | | * [http://www.center4research.org/pdf/booklet04bc.pdf Surgery Choices for Women with Early-Stage Breast Cancer, National Cancer Institute] |
| * [http://www.center4research.org/bc071502.html Mastectomy vs.n Lumpectomy: Who Decides?, National Research Center for Women & Families] | | * [http://www.center4research.org/bc071502.html Mastectomy vs.n Lumpectomy: Who Decides?, National Research Center for Women & Families] |
| * Australia: ''Cancer Control Bulletin'' [http://www.sesiahs.health.nsw.gov.au/publications/cancerControl/26%20Alcohol.PDF Alcohol and cancer risk]
| |
|
| |
|
| ===Videos===
| | {{WikiDoc Help Menu}} |
| *[http://www.healthination.com/breast_cancer.php Health Video: Breast Cancer - Overview, Prevention and Treatment]
| | {{WikiDoc Sources}} |
|
| |
|
| [[Category:Disease state]] | | [[Category:Disease]] |
| [[Category:Types of cancer]] | | [[Category:Types of cancer]] |
| [[Category:Breast]] | | [[Category:Breast]] |
| Line 435: |
Line 86: |
| [[Category:Oncology]] | | [[Category:Oncology]] |
| [[Category:Mature chapter]] | | [[Category:Mature chapter]] |
| | | [[Category:Up-To-Date]] |
| [[ar:سرطان الثدي]]
| | [[Category:Oncology]] |
| [[bs:Tumori dojke]]
| | [[Category:Medicine]] |
| [[bg:Рак на гърдата]]
| | [[Category:Gynecology]] |
| [[da:Brystkræft]]
| | [[Category:Surgery]] |
| [[de:Brustkrebs]]
| |
| [[es:Cáncer de mama]]
| |
| [[fa:سرطان پستان]]
| |
| [[fr:Cancer du sein]]
| |
| [[hr:Rak dojke]]
| |
| [[id:Kanker payudara]]
| |
| [[it:Carcinoma mammario]]
| |
| [[he:סרטן השד]]
| |
| [[ka:მკერდის კიბო]]
| |
| [[mk:Рак на дојка]]
| |
| [[ms:Penyakit barah payudara]]
| |
| [[nl:Borstkanker]]
| |
| [[ja:乳癌]]
| |
| [[no:Brystkreft]]
| |
| [[pl:Rak sutka]]
| |
| [[pt:Câncer de mama]]
| |
| [[ro:Cancer mamar]]
| |
| [[ru:Злокачественные новообразования молочной железы]]
| |
| [[simple:Breast cancer]]
| |
| [[sk:Karcinóm prsníka]]
| |
| [[fi:Rintasyöpä]]
| |
| [[sv:Bröstcancer]]
| |
| [[th:มะเร็งเต้านม]] | |
| [[vi:Ung thư vú]] | |
| [[tr:Meme kanseri]] | |
| [[ur:سرطان پستان]] | |
| [[zh:乳癌]] | |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |